1.CT myelography: application in detecting the site of spontaneous cerebrospinal fluid leaks
Jin WANG ; Qiaowei ZHANG ; Peilin LU ; Li WANG ; Xingyue HU
Chinese Journal of Neurology 2009;42(5):319-322
Objective To evaluate the application of CT myelography (CTM) in detecting the site of spontaneous cerebrospinal fluid (CSF) leaks and analyze it's imaging features.Methods Six patients (3 women and 3 men) with spontaneous intracranial hypotension (SIH) were included, who met the criteria of the International Headache Classification (2nd edition, 2004). Five patients subsequently underwent whole spine MRI and all 6 patients underwent CTM. Autologous blood mixed with omnipaque (300 mg/ml) was injected followed by selective puncture at the leak site indicated by CTM. Results MRI was failed to find leak site in the 5 patients, whereas CTM successfully found leak sites in all 6 patients. There were 1 to 7 leak sites respectively with an average of 4.2 sites (totally 25 points). Leak sites at cervical (12 sites) and thoracic (12 sites) were more frequent than at lumbar (1 site). CTM was featured by linear leakage of the contrast medium along the spinal nerve roots, paraspinal collections of hyper-density contrast medium and beak-like enlargement of the nerve sleeves. All patients responded well to the treatment, with complete resolution of symptoms. Conclusion CTM has been shown to be a study of choice to accurately define the location and extent of a CSF leak.
2.The value of multiple neurophysiological tests in the diagnosis of diabetic peripheral neuropathy
Qi SUN ; Lu SHI ; Hong JIANG ; Xingyue HU
Chinese Journal of Physical Medicine and Rehabilitation 2015;37(11):867-870
Objective To evaluate the value of united nerve electrophysiological tests in the diagnosis of diabetic peripheral neuropathy (DNP).Methods The quantitative temperature threshold (QTT), including the cold sensation threshold (CST) , thermal sensation threshold (WST), cold pain threshold (CPT) and thermal pain threshold (HPT), sympathetic skin response (SSR) and nerve conduction velocity (NCV) were measured for 85 diabetic patients.Results The abnormal rate of QTT was 84.71% , significantly higher than that of SSR and NCV (56.47% and 31.76% respectively).However, no significant difference was found in the abnormal rate of QTT between the DPN asymptomatic group and DPN symptomatic group (78.85% and 93.94% respectively).There was significant difference in the abnormal rate of SSR (48.08% and 69.70% respectively) and the abnormal rate of NCV (19.23% and 51.52% respectively) between the above two groups(P < 0.05).There was no difference in the abnormal rate of QTT for patients with short or long course of disease (77.77% and 89.80% respectively), but significant difference in the abnormal rate of SSR (44.44% and 65.31% respectively) and the abnormal rate of NCV (19.44% and 40.82% respectively) Conclusion The abnormal rate of QTT was highest in detecting the diabetic patients, and it is not related to clinical symptoms or disease course.However, the abnormal rates of SSR and NCV were related to clinical symptoms and course.It is more sensitive to diagnose DPN using united electrophysiological tests of QTT, SSR and NCV.
3. The effect of antiviral therapy on the clinical outcomes of chronic hepatitis B
Xingyue WANG ; Lu ZHANG ; Minghui LI
Chinese Journal of Experimental and Clinical Virology 2017;31(6):570-575
Chronic hepatitis B (CHB) is a chronic inflammation of liver which infected with the hepatitis B virus (HBV). The chronic inflammation of liver will lead to cirrhosis, complications of liver decompensation from cirrhosis, hepatocellular carcinoma (HCC) and even death.There are two kinds of drugs are available for the treatment: interferon(IFN)which including IFN-αand pegylated IFN, and nucleoside analog(NAs) which including lamivudine, adefovir dipivoxil, entecavir, telbivudine and Tenofovir disoproxil fumarate.We will describe the mechanisms of the CHB, INF and NAs to state the effect on the clinical outcome(cirrhosis, complications from cirrhosis, hepatocellular carcinoma and death) of the therapy of antiviral therapies.
4.Risk factors for age-related macular degeneration in elderly Chinese population in Shenyang of China.
LiHong JIA ; XueLi SHEN ; Rui FAN ; Yan SUN ; XingYue PAN ; HongMei YANH ; Lu LIU
Biomedical and Environmental Sciences 2011;24(5):506-511
OBJECTIVEThe paper aims to evaluate the risk factors for age-related macular degeneration (AMD) in elderly Chinese population in Shenyang, a northeast city of China.
METHODSA case-control study was conducted to investigate the risk factors for the prevalence of AMD. Ninety three AMD patients diagnosed by a complete ophthalmic examination were recruited as cases from the outpatient departments of two eye hospitals in Shenyang, while 108 normal subjects of similar age and sex were recruited as controls. A questionnaire was administered among both cases and controls.
RESULTSAMD patients aged 60 years and older accounted for 75.3%. There were significantly higher educational levels, shorter smoking history, less sunlight exposure and cataract, and higher proportion of antioxidants intake in controls than in AMD patients. The frequency of intake of fruits, legumes, fish and shrimps was significantly higher in controls than in AMD patients. In a binary logistic regression analysis, smoking and cataract were the risk factors for AMD (OR: 4.44, 95% CI: 2.27-8.69; OR: 4.47, 95% CI: 2.26-8.85 respectively). The high educational background was a protective factor for AMD (OR: 0.761, 95% CI: 0.51-0.98).
CONCLUSIONA low educational background, smoking and cataract are associated with a higher prevalence of AMD.
Aged ; Aged, 80 and over ; Antioxidants ; Case-Control Studies ; Cataract ; complications ; China ; epidemiology ; Dietary Supplements ; utilization ; Educational Status ; Feeding Behavior ; Female ; Humans ; Macular Degeneration ; epidemiology ; etiology ; Male ; Middle Aged ; Risk Factors ; Smoking ; adverse effects ; Sunlight ; adverse effects
5. Changes of peripheral blood during the antiviral treatment with Peg-IFNα-2 a for patients with chronic hepatitis B and the relationship between the changes and effect
Zhenzhen LI ; Shuling WU ; Lu ZHANG ; Yao LU ; Weihua CAO ; Xingyue WANG ; Chongping RAN ; Tianlin QI ; Hongxiao HAO ; Ge SHEN ; Hongyu LIU ; Min CHANG ; Leiping HU ; Minghui LI ; Yao XIE
Chinese Journal of Experimental and Clinical Virology 2017;31(5):446-449
Objective:
To observe the changes of peripheral blood picture of CHB with Peg-IFN, and explored the relationship between the changes and decline of HBV DNA, clearance of HBsAg.
Methods:
Patients with CHB treated with Peg-IFN α-2 a in the Second Division of Liver Disease in Beijing Ditan Hospital were monitored for blood routine examination and Liver function, kidney function, thyroid function of baseline and weeks 2, 4, 8, 12, 24, 36, 48, and weeks 12, 24, and 48 after the end of treatment for chronic hepatitis B, and HBV DNA, HBsAg.
Results:
The decrease of peripheral blood cells began to occur at week 2 of treatment. For CHB with HBeAg negative patients, white blood cells, lymphocyte, neutrophils, hemoglobin and platelets significantly decreased at 2 weeks, while a minimum value occurred at 48 weeks. The recovery was obvious at the end of treatment (48 weeks), and reached pre-treatment levels at 48 weeks after the end of treatment. For CHB with HBeAg positive patients, white blood cells, neutrophils, hemoglobin and platelets significantly decreased at 2 weeks, while a minimum value was found at 36-48 weeks. The recovery was obvious at the end of treatment (48 weeks), and reached pre-treatment levels at 48weeks after the end of treatment. For patients with CHB, hemoglobin declined by more than13.64% at 36th week, which means that the patient would have a predictive significance for decrease of HBV DNA, and drops of more than 0.33% at 2nd week means that the patient would have a predictive significance for clearance of HBsAg.
Conclusions
During the treatment with interferon, the variation regularity of blood picture for predicting result have a certain effect, which may help predict and monitor the change of blood picture in clinical work.
6. Changes in peripheral blood during the antiviral treatment with Peg-IFNα-2 a and ribavirin for patients with chronic hepatitis C and the relationship between the changes and effect
Zhenzhen LI ; Hongxiao HAO ; Lu ZHANG ; Yao LU ; Weihua CAO ; Xingyue WANG ; Chongping RAN ; Tianlin QI ; Shuling WU ; Ge SHEN ; Ru LIU ; Min CHANG ; Leiping HU ; Minghui LI ; Yao XIE
Chinese Journal of Experimental and Clinical Virology 2017;31(6):545-548
Objective:
To observe the changes of peripheral blood image of chronic hepatitis C (CHC) patients treated with pegylated interferon (Peg-IFN) and ribavirin, and explore the relationship between the changes and serum virological respose (SVR).
Methods:
Patients with CHC treated with Peg-IFN α-2 a and ribavirin in the Second Division of Liver Disease in Beijing Ditan Hospital were monitored for peripheral blood cells routine examination and Liver function, kidney function, thyroid function at baseline and week 2, 4, 8, 12, 24, 36, 48, and week 12, 24, 48 after the end of treatment for chronic hepatitis C, and HCV RNA.
Results:
The decrease of peripheral blood cell counts began to appear at week 2 of treatment. For CHC patients without cirrhosis, white blood cells, lymphocyte, hemoglobin and platelets at week 2, while minimum values were seen at week 36, and the neutrophils reached the minimum value to at week 24. Significant recovery of the peripheral blood changes was seen at the end of treatment (48 weeks), and reached pre-treatment levels at week 48 after the end of treatment. For CHC patients with cirrhosis, white blood cells, lymphocytes, hemoglobin and platelets significantly decreased at week 2, while neutrophils reached a minimum value at 2 weeks. And hemoglobin and platelets reached a minimum value at 24 weeks, and the white blood cells reached the minimum value at weeks 24-36 besides lymphocyte reached the minimum value at week 36. Significant recovery was seen at the end of treatment (48 weeks), and the blood cell counts reached pre-treatment levels at 48 weeks after the end of treatment. For patients with CHC, hemoglobin decreased by more than 27.47% at week 4, which means that the patient would have a predictive significance for SVR, as well as the of PLT reduction by more than 36.96% at week 8.
Conclusions
During the treatment with Peg-interferon and ribavirin, the variation of blood picture has some predicting effect, which predicts the result of antiviral treatment.
7. Study on the association between the efficacy of peg-IFN and the complexity of TP and RT in chronic hepatitis B
Tianlin QI ; Xingyue WANG ; Chongping RAN ; Weihua CAO ; Lu ZHANG ; Yao LU ; Hongxiao HAO ; Shuling WU ; Ruyu LIU ; Min CHANG ; Leiping HU ; Minghui LI ; Yao XIE
Chinese Journal of Experimental and Clinical Virology 2019;33(1):74-78
Objective:
To explore the association between the efficacy of peg-IFN and the complexity of TP and RT regions of hepatitis B virus (HBV) in chronic hepatitis B.
Methods:
Patients with HBeAg positive, HBV DNA positive chronic hepatitis B were given peg-interferon 180 μg once a week for subcutaneous injection, and baseline information was collected from baseline and after 12 weeks’ treatment. The baseline HBV DNA TP and RT fragments were amplified, database, high-throughput sequencing, and the average genetic distance calculation.
Results:
Data of 108 patients were analyzed by logistic regression. RT area fragment Markov distance and TP area fragment Shannon quotient for HBV DNA response were calculated. ALT level is good for HBeAg response. HBsAg level is bad for HBsAg response.
Conclusions
The complexity of the baseline TP and RT regions may be associated with the efficacy of peg-interferon therapy for CHB.
8.Safety and efficacy of botulinum toxin type A made in China for treatment of post-stroke upper limb spasticity: a randomized double-blind controlled trial
Yingmai YANG ; Qi LIANG ; Xinhua WAN ; Lin WANG ; Suling CHEN ; Qiang WU ; Xueping ZHANG ; Shengyuan YU ; Huifang SHANG ; Xingyue HU ; Jiahong LU ; Enxiang TAO ; Zhiyu NIE ; Xudong PAN ; Ronghua TANG ; Baorong ZHANG ; Jun CHEN ; Hongyu TAN ; Hongjuan DONG ; Jian'an LI ; Weifeng LUO ; Chen YAO
Chinese Journal of Neurology 2018;51(5):355-363
Objective To evaluate the safety and efficacy of botulinum toxin type A for injection in the treatment of post-stroke upper limb spasticity (dosage was 200 U,or 240 U if combined with thumb spasticity).Methods The study was a multi-center,stratified block randomized,double-blind,placebocontrolled trial.All the qualificd subjects were from 15 clinical centers from September 2014 to February 2016.They were randomized (2∶1) to injections of botulinum toxin type A made in China (200-240 U;n =118) or placebo (n =60) in pivotal phase after informed consent signed.The study was divided into two stages.The pivotal trial phase included a one-week screening,12-week double-blind treatment,followed by an expanded phase which included six-week open-label treatment.The tone of the wrist,finger,thumb flexors was assessed at baseline and at weeks 0,1,4,6,8,12,16 and 18 using Modified Ashworth Scale (MAS),disability in activities of daily living was rated using the Disability Assessment Scale and impaction on pain,muscle tone and deformity was assessed using the Global Assessment Scale.The primary endpoint was the score difference between botulinum toxin type A and placebo groups in the tone of the wrist flexor using MAS at six weeks compared to baseline.Results Muscle tone MAS score in the wrist flexor of botulinum toxin type A and placebo groups at six weeks changed-1.00 (-2.00,-1.00) and 0.00 (-0.50,0.00) respectively from baseline.Botulinum toxin type A was significantly superior to placebo for the primary endpoint (Z =6.618,P < 0.01).The safety measurement showed 10 subjects who received botulinum toxin type A had 13 adverse reactions,with an incidence of 8.47% (10/118),and three subjects who received placebo had three adverse reactions,with an incidence of 5.00% (3/60) during the pivotal trial phase.All adverse reactions were mild to moderate,none serious.There was no significant difference in adverse reactions incidence between the botulinum toxin type A and the placebo groups.During the expanded phase three subjects had four adverse reactions and the incidence was 1.95%.All adverse reactions were mild,none serious.Conclusion Botulinum toxin type A was found to be safe and efficacious for the treatment of post-stroke upper limb spasticity.Clinical Trial Registration:China Drug Trials,CTR20131191
9.Down-regulation of miR-205-5p enhances pro-apoptotic effect of 3-bromopyruvate on human nasopharyngeal carcinoma CNE2Z cells.
Zongfen SHI ; Pei ZHANG ; Xingyue LU ; Chenlu ZHU ; Changjiang CHEN ; Surong ZHAO ; Hao LIU
Journal of Southern Medical University 2019;39(10):1166-1172
OBJECTIVE:
To investigate the effect of down-regulation of miR-205-5p on 3-bromopyruvate-induced apoptosis in human nasopharyngeal carcinoma CNE2Z cells.
METHODS:
Nasopharyngeal carcinoma CNE2Z cells were transfected with miR- 205-5p-mimic or miR-205-5p-inhibitor, treated with 80 μmol/L 3-bromopyruvate alone, or exposed to both of the treatments. The proliferation of the treated cells was examined with MTT assay, and early apoptosis of the cells was detected using a mitochondrial membrane potential detection kit (JC-1). DAPI fluorescence staining was used to detect morphological changes of the cell nuclei and late cell apoptosis; Annexin V-FITC/PI double staining was employed to detect the cell apoptosis rate. Western blotting was used to detect the expressions of Bcl-2, Bax, Mcl-1 and Bak proteins.
RESULTS:
Exposure to 3-bromopyruvate significantly inhibited the proliferation of CNE2Z cells, and increasing the drug concentration and extending the treatment time produced stronger inhibitory effects. Treatment with 80 μmol/L 3-bromopyruvate for 24, 48 and 72 h resulted in inhibition rates of (45.7±1.21)%, (64.4±2.02)% and (78.3±1.55)% in non-transfected CNE2Z cells, respectively; the inhibition rates were (27.7±1.04)%, (34.8±2.10)% and (44.3±1.57)% in the cells transfected with miR-205-5p-mimic, and were (80.5 ± 0.94)%, (87.9 ± 0.50)% and (93.8 ± 1.16)% in cells transfected with miR-205-5p-inhibitor, respectively. The results of mitochondrial membrane potential detection showed that the relative proportion of red and green fluorescence decreased significantly in miR-205-5p-inhibitor-transfected cells with 3-bromopyruvate treatment. Combined treatment of the cells with 3-bromopyruvate and miR-205-5p-inhibitor transfection obviously increased nuclear fragmentation and nuclear pyknosis and significantly increased cell apoptotic rate as compared with the two treatments alone ( < 0.01), causing also decreased expressions of Bcl-2 and Mcl-1 proteins and increased expressions of Bax and Bak proteins.
CONCLUSIONS
Inhibition of miR-205-5p enhances the proapototic effect of 3-bromopyruvate in CNE2Z cells possibly in relation to the down-regulation of Mcl-1 and Bcl-2 and the up-regulation of Bak and Bax proteins.
10. Protectivity of hepatitis B surface antibody in children between 1 and 3 years after successful blocking of mother-to-child transmission
Weihua CAO ; Ying ZHNAG ; Minghui LI ; Chongping RAN ; Tianlin QI ; Xingyue WANG ; Yuhong HU ; Mingshu ZHOU ; Lu ZHANG ; Yao LU ; Shuling WU ; Ge SHEN ; Hongxiao HAO ; Min CHANG ; Leiping HU ; Ruyu LIU ; Wenhao HUA ; Wei YI ; Yao XIE
Chinese Journal of Experimental and Clinical Virology 2017;31(5):401-404
Objective:
To investigate the change of hepatitis B surface antibody (HBsAb) titer and its long-term protection and infection rates between 1 and 3-year-old children whose mothers were chronic hepatitis B pregnant woman with HBeAg positive and high viral load after successful blocking of mother-to-child transmission.
Methods:
One-year-old children whose mothers were hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive, with HBV DNA≥106IU/ml were enrolled, then were followed up till 3 years old, and tested the five serological markers of hepatitis B and biochemical parameters at the age of one and three years respectively, and analyzed HBsAb titer, positive rate, negative rate and infection rate of 1 to 3-year-old children without enhanced vaccination; meanwhile, data of HBsAb titers at the age of 7 months were collected HBsAb titer, positive rate, and negative rate were analyzed.
Results:
Totally 264 1-year-old children were enrolled into the study, including 178 children without enhanced vaccination between seven months and 1 year of age, and 114 children without enhanced vaccination between 1 year and 3 years of age. Our result showed that there were no infected children at the age between 1 and 3 years. HBsAb titer decreased from 7 months to 1 year old and dropped from 1 000 IU/L to 509.43 IU/L (